A Phase II Prospective Immune Neoadjuvant Therapy Study od Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IONESCO
- 08 Mar 2017 Status changed from not yet recruiting to recruiting.
- 14 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Feb 2017.
- 21 Oct 2016 New trial record